News

Get Alerts by Email

Feb 7, 2018

Galmed Granted "Preferred Technological Enterprise" Status Which May Provide the Company With Significant Financial Benefits

Galmed Pharmaceuticals, Ltd. (Nasdaq: GLMD), ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
Jan 2, 2018

Galmed Pharmaceuticals Raised Gross Proceeds of $11.6 Million Under ATM Programs During December 2017

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
Nov 27, 2017

Galmed Pharmaceuticals to Present at HEP DART 2017 Meeting

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
- Photos 1
Nov 9, 2017

Galmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST -

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of...
Nov 7, 2017

Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis,...
- Photos 1

Show per page